menu search

Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational<...

November 4, 2023, 12:00 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an ...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an ...

November 3, 2023, 8:30 pm

Gilead to present late breaking data and real world evidence highlighting key hepatitis indications at the liver meeting® 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America...

November 3, 2023, 11:00 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Hillevax to present at upcoming investor conferences

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerci...

November 1, 2023, 4:48 pm

Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...

October 31, 2023, 9:15 am

Perimeter medical imaging ai initiates new clinical trial site at university of washington's fred hutch cancer center

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) said it has initiated an additional clinical trial site at the Fred Hutch Cancer Center at the U...

October 31, 2023, 8:08 am

New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau ta...

October 25, 2023, 2:51 pm

Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n...

October 25, 2023, 7:30 am

: lipella pharmaceuticals stock more than doubles in 3 days as fda approves ind for olp treatment

Shares of Lipella Pharmaceuticals Inc. LIPO rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company’s ...

October 20, 2023, 2:47 pm

Lipella pharmaceuticals stock more than doubles in 3 days as fda approves ind for olp treatment

Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology com...

October 20, 2023, 10:47 am

Nkarta (nktx) rallies 112% as fda clears ind for lupus drug

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidat...

October 18, 2023, 12:03 pm

Intellia's (ntla) hae candidate gets ema's prime designation

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based ...

October 16, 2023, 2:17 pm

Terns pharmaceuticals announces global phase 1 clinical trial design of tern-701 for the treatment of chronic myeloid leukemia

investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insi...

October 16, 2023, 12:05 pm

Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo

Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous ...

October 15, 2023, 10:05 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm


Search within

Pages Search Results: